NEW YORK, N.Y. – February 1, 2023 – Castor, a leading provider of clinical trial technology to democratize clinical research, today announced the appointment of Brad Hightower, a leading clinical trials executive, to its advisory board.
Brad brings more than 10 years of experience in clinical research, as the former Executive Director of the Oklahoma Heart Hospital Research Foundation. He founded Hightower Clinical, a research network that offers services that support researchers and patients to access trials easily.
“I am excited to join Castor’s Advisory Board,” said Brad Hightower. “I have been a fierce advocate for patients’ access and seeing little changes in how we conduct trials that truly benefit our patient population. I believe in the potential of technology to fill in this gap. Castor is bringing the right technology to connect patients and study teams.”
Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide.
Laura McLoughlin, [email protected]
Kimberly Ha, [email protected]